181 related articles for article (PubMed ID: 21960118)
1. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.
Antonarakis ES; Zahurak ML; Lin J; Keizman D; Carducci MA; Eisenberger MA
Cancer; 2012 Mar; 118(6):1533-42. PubMed ID: 21960118
[TBL] [Abstract][Full Text] [Related]
2. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
[TBL] [Abstract][Full Text] [Related]
3. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Lin J; Zahurak M; Beer TM; Ryan CJ; Wilding G; Mathew P; Morris M; Callahan JA; Gordon G; Reich SD; Carducci MA; Antonarakis ES
Urol Oncol; 2013 Jul; 31(5):581-8. PubMed ID: 21816640
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy.
Schweizer MT; Zhou XC; Wang H; Yang T; Shaukat F; Partin AW; Eisenberger MA; Antonarakis ES
Ann Oncol; 2013 Nov; 24(11):2881-6. PubMed ID: 23946329
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
6. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Markowski MC; Chen Y; Feng Z; Cullen J; Trock BJ; Suzman D; Antonarakis ES; Paller CJ; Rosner I; Han M; Walsh PC; Partin AW; Eisenberger M
Clin Genitourin Cancer; 2019 Dec; 17(6):470-475.e1. PubMed ID: 31530439
[TBL] [Abstract][Full Text] [Related]
7. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Liu G; Chen YH; Kolesar J; Huang W; Dipaola R; Pins M; Carducci M; Stein M; Bubley GJ; Wilding G
Urol Oncol; 2013 Feb; 31(2):211-8. PubMed ID: 21784672
[TBL] [Abstract][Full Text] [Related]
8. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
Antonarakis ES; Chen Y; Elsamanoudi SI; Brassell SA; Da Rocha MV; Eisenberger MA; McLeod DG
BJU Int; 2011 Aug; 108(3):378-85. PubMed ID: 21091976
[TBL] [Abstract][Full Text] [Related]
9. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
Antonarakis ES; Feng Z; Trock BJ; Humphreys EB; Carducci MA; Partin AW; Walsh PC; Eisenberger MA
BJU Int; 2012 Jan; 109(1):32-9. PubMed ID: 21777360
[TBL] [Abstract][Full Text] [Related]
10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
[TBL] [Abstract][Full Text] [Related]
12. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
Lee M; Hong H; Kim W; Zhang L; Friedlander TW; Fong L; Lin AM; Small EJ; Wei XX; Rodvelt TJ; Miralda B; Stocksdale B; Ryan CJ; Aggarwal R
Clin Genitourin Cancer; 2019 Feb; 17(1):e92-e96. PubMed ID: 30327180
[TBL] [Abstract][Full Text] [Related]
13. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
14. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
[TBL] [Abstract][Full Text] [Related]
15. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
16. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
17. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
20. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
